SCHEMBL23930634

SCHEMBL23930634

C=CCOc1cc(C(=O)OC)on1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.43
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 3/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
CHRNA4 P43681 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CASP3 P42574 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35
P2RX3 P56373 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210975 0.91 SMPD1 (0.38) SMPD1NR1H2NR1H3SMN1; SMN2MAPT
SCHEMBL29808909 0.85 SMPD1 (0.42) SMPD1SMN1; SMN2MAPTPOLBLMNA
SCHEMBL7896956 0.81 SMPD1 (0.50) SMPD1NR1H2NR1H3SMN1; SMN2MAPT
SCHEMBL9111932 0.81 SMPD1 (0.40) SMPD1NR1H2NR1H3SMN1; SMN2MAPT
SCHEMBL7311748 0.80 SMPD1 (0.46) SMPD1NR1H2NR1H3MAPTNPC1
SCHEMBL23930570 0.79 SMPD1 (0.37) SMPD1MAPTTSHRKDM4EMTNR1A
SCHEMBL5888236 0.79 SMPD1 (0.58) SMPD1NR1H2NR1H3NPC1POLB
SCHEMBL25171017 0.79 SMPD1 (0.55) SMPD1NR1H2NR1H3MAPTPOLB
SCHEMBL4758485 0.79 SMPD1 (0.45) SMPD1NR1H2NR1H3SMN1; SMN2NPC1
SCHEMBL6966899 0.78 KDM4E (0.42) SMPD1MAPTPOLBLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697979-B Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2025-06-24 CN disclosed
CN-114729004-B Heterocyclic compounds 日商泛美克斯股份有限公司 2025-06-03 CN disclosed
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN disclosed
CN-114729004-A Heterocyclic compounds 日商泛美克斯股份有限公司 2022-07-08 CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG SMPD1 510/4885NR1H2 1558/4885NR1H3 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.